Drugs / KLU156
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07811908 | Feb 2026 → Feb 2027 expected | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT05750628 | Jan 2024 → Jun 2026 overdue | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-12 | Novartis Pharmaceuticals | Results Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance novartis.com ↗
Novartis today announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-12 | Novartis Pharmaceuticals | Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance novartis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KLU156 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07811908 ↗ |
| Route | Oral | “oral sachet KLU156 (KAF156 + lumefantrine)” NCT05750628 ↗ |